Showing results (141-150 of 223) with videos related to
Sort By:
Pageof 23
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 20, 2009
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trialElijah W Stommel, Jeffrey A Cohen, Camilo E Fadul, et al.Neurology|January 24, 2024
Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor EncephalitisAnnalisa Morgan, Yadi Li, Nicolas R Thompson, et al.Annals of Clinical and Translational Neurology|January 22, 2024
Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disordersSanem P Uysal, Yadi Li, Nicolas R Thompson, et al.The Lancet. Neurology|November 21, 2022
Multiple sclerosis progression: time for a new mechanism-driven frameworkTanja Kuhlmann, Marcello Moccia, Timothy Coetzee, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 27, 2015
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A Cohen, Bhupendra Khatri, Frederik Barkhof, et al.Journal of the Neurological Sciences|October 24, 2019
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-upBrandi Vollmer, Daniel Ontaneda, Haleigh Harris, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 15, 2019
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimodJeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, et al.Neurology|July 17, 2024
Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup AnalysesMitzi J Williams, Lilyana Amezcua, Stanley L Cohan, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 26, 2018
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trialJeffrey A Cohen, Samuel F Hunter, Theodore R Brown, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2017
Switching from branded to generic glatiramer acetate: 15-month GATE trial extension resultsKrzysztof Selmaj, Frederik Barkhof, Anna N Belova, et al.Pageof 23